{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["anticancer", "medicinal plants", "natural products", "pharmacophore", "toxicity", "virtual screening"]], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "27445461", "DateCompleted": {"Year": "2017", "Month": "05", "Day": "17"}, "DateRevised": {"Year": "2018", "Month": "11", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "07", "Day": "04"}], "ELocationID": ["10.2147/DDDT.S108118"], "Language": ["eng"], "Journal": {"ISSN": "1177-8881", "JournalIssue": {"Volume": "10", "PubDate": {"Year": "2016"}}, "Title": "Drug design, development and therapy", "ISOAbbreviation": "Drug Des Devel Ther"}, "ArticleTitle": "Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants.", "Pagination": {"StartPage": "2137", "EndPage": "2154", "MedlinePgn": "2137-54"}, "Abstract": {"AbstractText": ["Molecular modeling has been employed in the search for lead compounds of chemotherapy to fight cancer. In this study, pharmacophore models have been generated and validated for use in virtual screening protocols for eight known anticancer drug targets, including tyrosine kinase, protein kinase B \u03b2, cyclin-dependent kinase, protein farnesyltransferase, human protein kinase, glycogen synthase kinase, and indoleamine 2,3-dioxygenase 1. Pharmacophore models were validated through receiver operating characteristic and G\u00fcner-Henry scoring methods, indicating that several of the models generated could be useful for the identification of potential anticancer agents from natural product databases. The validated pharmacophore models were used as three-dimensional search queries for virtual screening of the newly developed AfroCancer database (~400 compounds from African medicinal plants), along with the Naturally Occurring Plant-based Anticancer Compound-Activity-Target dataset (comprising ~1,500 published naturally occurring plant-based compounds from around the world). Additionally, an in silico assessment of toxicity of the two datasets was carried out by the use of 88 toxicity end points predicted by the Lhasa's expert knowledge-based system (Derek), showing that only an insignificant proportion of the promising anticancer agents would be likely showing high toxicity profiles. A diversity study of the two datasets, carried out using the analysis of principal components from the most important physicochemical properties often used to access drug-likeness of compound datasets, showed that the two datasets do not occupy the same chemical space."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Martin-Luther University of Halle-Wittenberg, Halle (Saale), Germany; Department of Chemistry, University of Buea, Buea, Cameroon."}], "LastName": "Ntie-Kang", "ForeName": "Fidele", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Martin-Luther University of Halle-Wittenberg, Halle (Saale), Germany; Department of Chemistry, University of Buea, Buea, Cameroon."}], "LastName": "Simoben", "ForeName": "Conrad Veranso", "Initials": "CV"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Martin-Luther University of Halle-Wittenberg, Halle (Saale), Germany."}], "LastName": "Karaman", "ForeName": "Berin", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Interuniversity Institute For Biostatistics and Statistical Bioinformatics (I-BioStat), University of Hasselt, Hasselt, Belgium."}], "LastName": "Ngwa", "ForeName": "Valery Fuh", "Initials": "VF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemical Bioactivity Information Centre, Harrogate, UK."}], "LastName": "Judson", "ForeName": "Philip Neville", "Initials": "PN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Martin-Luther University of Halle-Wittenberg, Halle (Saale), Germany."}], "LastName": "Sippl", "ForeName": "Wolfgang", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Faculty of Science, University of Douala, Douala, Cameroon."}], "LastName": "Mbaze", "ForeName": "Luc Meva'a", "Initials": "LM"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Drug Des Devel Ther", "NlmUniqueID": "101475745", "ISSNLinking": "1177-8881"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Proto-Oncogene Proteins c-akt"}], "MeshHeadingList": [{"QualifierName": ["administration & dosage", "chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Computer Simulation"}, {"QualifierName": [], "DescriptorName": "Databases, Factual"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Models, Molecular"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["chemistry", "metabolism", "pharmacology"], "DescriptorName": "Proto-Oncogene Proteins c-akt"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science. 2000;287(5460):1969\u20131973.", "ArticleIdList": ["10720316"]}, {"Citation": "WHO Media Centre [webpage on the Internet]  Fast sheet N\u00ba 297. 2013.  [Accessed February 4, 2014].  Available from:  http://www.who.int/mediacentre/factsheets/fs297/en/index.html."}, {"Citation": "[webpage on the Internet]  Globocan Fast Stats. 2008.  [Accessed August 4, 2013].  Available from:  http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php."}, {"Citation": "Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep. 2000;17(3):215\u2013234.", "ArticleIdList": ["10888010"]}, {"Citation": "Hostettmann K, Terreaux C. Search for new lead compounds from higher plants. Chimia. 2000;54(11):652\u2013657."}, {"Citation": "Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today. 2008;13(3):161\u2013171.", "ArticleIdList": ["18275914"]}, {"Citation": "Salim AA, Chin YW, Kinghorn AD. Drug discovery from plants. In: Ramawat KG, Merillon JM, editors. Bioactive Molecules and Medicinal Plants. Heidelberg: Springer; 2008. pp. 1\u201324."}, {"Citation": "Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. J Nat Prod. 2011;74(6):1539\u20131555.", "ArticleIdList": ["PMC3158731", "21650152"]}, {"Citation": "Grothaus PG, Cragg GM, Newman DJ. Plant natural products in anticancer drug discovery. Curr Org Chem. 2010;14(16):1781\u20131791."}, {"Citation": "Ashutosh K. Medicinal Chemistry. New Delhi, India: New Age International Ltd; 2007. p. 794."}, {"Citation": "Desai AG, Qazi GN, Ganju RK, et al. Medicinal plants and cancer chemoprevention. Curr Drug Metab. 2008;9(7):581\u2013591.", "ArticleIdList": ["PMC4160808", "18781909"]}, {"Citation": "Heinrich M, Bremner P. Ethnobotany and ethnopharmacy \u2013 their role for anti-cancer drug development. Curr Drug Targets. 2006;7(3):239\u2013245.", "ArticleIdList": ["16515525"]}, {"Citation": "Cragg GM, Newman DJ. Nature: a vital source of leads for anticancer drug development. Phytochem Rev. 2009;8(2):313\u2013331."}, {"Citation": "Holl\u00f3sy F, K\u00e9ri G. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. Curr Med Chem Anticancer Agents. 2004;4(2):173\u2013197.", "ArticleIdList": ["15032721"]}, {"Citation": "Clardy J, Walsh C. Lessons from natural molecules. Nature. 2004;432(7019):829\u2013837.", "ArticleIdList": ["15602548"]}, {"Citation": "Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Ther. 2003;99(1):1\u201313.", "ArticleIdList": ["12804695"]}, {"Citation": "Lucas DM, Still PC, P\u00e9rez LB, Grever MR, Kinghorn AD. Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets. 2010;11(7):812\u2013822.", "ArticleIdList": ["PMC2892601", "20370646"]}, {"Citation": "Wang HK, Lee KH. Plant-derived anticancer agents and their analogs currently in clinical use or in clinical trials. Bot Bull Acad Sinica. 1997;38:225\u2013235."}, {"Citation": "Pan L, Chai H, Kinghorn AD. The continuing search for antitumor agents from higher plants. Phytochem Lett. 2010;3(1):1\u20138.", "ArticleIdList": ["PMC2836022", "20228943"]}, {"Citation": "Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1):72\u201379.", "ArticleIdList": ["16009521"]}, {"Citation": "Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78(5):431\u2013441.", "ArticleIdList": ["16198377"]}, {"Citation": "Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SP. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem. 2005;13(21):5892\u20135908.", "ArticleIdList": ["16129603"]}, {"Citation": "Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009;109(7):3012\u20133043.", "ArticleIdList": ["19422222"]}, {"Citation": "Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med. 2006;27(1):1\u201393.", "ArticleIdList": ["16105678"]}, {"Citation": "Nobili S, Lippi D, Witort E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res. 2009;59(6):365\u2013378.", "ArticleIdList": ["19429468"]}, {"Citation": "Lee KH. Anticancer drug design based on plant-derived natural products. J Biomed Sci. 1999;6(4):236\u2013250.", "ArticleIdList": ["10420081"]}, {"Citation": "Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol. 2007;9(12):767\u2013776.", "ArticleIdList": ["18158980"]}, {"Citation": "Connors T. Anticancer drug development: the way forward. Oncologist. 1996;1(3):180\u2013181.", "ArticleIdList": ["10387985"]}, {"Citation": "Fadeyi SA, Fadeyi OO, Adejumo AA, Okoro C, Myles EL. In vitro anticancer screening of 24 locally used Nigerian medicinal plants. BMC Complement Altern Med. 2013;13(1):79.", "ArticleIdList": ["PMC3635908", "23565862"]}, {"Citation": "Ntie-Kang F, Zofou D, Babiaka SB, et al. AfroDb: a select highly potent and diverse natural product library from African medicinal plants. PLoS One. 2013;8(10):e78085.", "ArticleIdList": ["PMC3813505", "24205103"]}, {"Citation": "Sawadogo WR, Schumacher M, Teiten MH, Dicato M, Diederich M. Traditional West African pharmacopeia, plants and derived compounds for cancer therapy. Biochem Pharmacol. 2012;84(10):1225\u20131240.", "ArticleIdList": ["22846603"]}, {"Citation": "Ntie-Kang F, Nwodo JN, Ibezim A, et al. Molecular modeling of potential anticancer agents from African medicinal plants. J Chem Inf Model. 2014;54(9):2433\u20132450.", "ArticleIdList": ["25116740"]}, {"Citation": "Ntie-Kang F, Lifongo LL, Judson PN, Sippl W, Efange SMN. How \u201cdrug-like\u201d are naturally occurring anti-cancer compounds? J Mol Model. 2014;20(1):1\u201313.", "ArticleIdList": ["24452907"]}, {"Citation": "Mangal M, Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013;41(D1):D1124\u2013D1129.", "ArticleIdList": ["PMC3531140", "23203877"]}, {"Citation": "Cragg GM, Newman DJ. Plants as a source of anti-cancer and anti-HIV agents. Ann Appl Biol. 2003;143(2):127\u2013133."}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311\u2013335.", "ArticleIdList": ["PMC3721181", "22316239"]}, {"Citation": "Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70(3):461\u2013477.", "ArticleIdList": ["17309302"]}, {"Citation": "Hostettmann K, Marston A, Ndjoko K, Wolfender JL. The potential of African plants as a source of drugs. Curr Org Chem. 2000;4(10):973\u20131010."}, {"Citation": "Sandberg F, Perera-Ivarsson P, El-Seedi HR. A Swedish collection of medicinal plants from Cameroon. J Ethnopharmacol. 2005;102(3):336\u2013343.", "ArticleIdList": ["16098698"]}, {"Citation": "El-Seedi HR, Burman R, Mansour A, et al. The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: discovery of an active cardiac glycoside from Urginea maritima. J Ethnopharmacol. 2013;145(3):746\u2013757.", "ArticleIdList": ["23228916"]}, {"Citation": "Efange SMN. Natural products: a continuing source of inspiration for the medicinal chemist. In: Iwu MM, Wootton JC, editors. Ethnomedicine and Drug Discovery; Advances in Phytomedicine. Vol. 1. Amsterdam, Netherlands: Elsevier Science; 2002. pp. 61\u201369."}, {"Citation": "DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151\u2013185.", "ArticleIdList": ["12606142"]}, {"Citation": "Klebe G. Virtual ligand screening strategies; perspective and limitations. Drug Discov Today. 2006;11(13):580\u2013594.", "ArticleIdList": ["PMC7108249", "16793526"]}, {"Citation": "Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel. 1998;1(1):4\u201315.", "ArticleIdList": ["19649784"]}, {"Citation": "Chen H, Yao K, Nadas J, et al. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One. 2012;7(5):e38261.", "ArticleIdList": ["PMC3365021", "22693608"]}, {"Citation": "Paul J, Gnanam R, Jayadeepa RM, Arul L. Anti cancer activity on Graviola, an exciting medicinal plant extract vs various cancer cell lines and a detailed computational study on its potent anti-cancerous leads. Curr Top Med Chem. 2013;13(14):1666\u20131673.", "ArticleIdList": ["23889049"]}, {"Citation": "Vyas VK, Ghate M, Goel A. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein Kinase B (PKB \u03b2) inhibitors. J Mol Graph Model. 2013;42:17\u201325.", "ArticleIdList": ["23507201"]}, {"Citation": "Fan Y, Shi LM, Kohn KW, Pommier Y, Weinstein JN. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. J Med Chem. 2001;44(20):3254\u20133263.", "ArticleIdList": ["11563924"]}, {"Citation": "Zhou H, Wu S, Zhai S, et al. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem. 2008;51(5):1242\u20131251.", "ArticleIdList": ["18257542"]}, {"Citation": "Chiang YK, Kuo CC, Wu YS, et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem. 2009;52(14):4221\u20134233.", "ArticleIdList": ["19507860"]}, {"Citation": "Kim DY, Kim KH, Kim ND, et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006;49(19):5664\u20135670.", "ArticleIdList": ["16970393"]}, {"Citation": "Ojima I, Chakravarty S, Inoue T, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A. 1999;96(8):4256\u20134261.", "ArticleIdList": ["PMC16319", "10200249"]}, {"Citation": "P\u00e9rez-Sacau E, D\u00edaz-Pen\u00e3te RG, Est\u00e9vez-Braun A, et al. Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line. J Med Chem. 2007;50(4):696\u2013706.", "ArticleIdList": ["17249647"]}, {"Citation": "Ntie-Kang F, Mbah JA, Mbaze LM, et al. CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med. 2013;13:88.", "ArticleIdList": ["PMC3637470", "23590173"]}, {"Citation": "Ntie-Kang F, Ongu\u00e9n\u00e9 PA, Scharfe M, et al. ConMedNP: a natural product library from medicinal plants in Central Africa. RSC Adv. 2014;4:409\u2013419."}, {"Citation": "Ntie-Kang F, Amoa Ongu\u00e9n\u00e9 P, Fotso GW, et al. Virtualizing the p-ANAPL library: a step towards drug discovery from African medicinal plants. PLoS One. 2014;9(3):e90655.", "ArticleIdList": ["PMC3944075", "24599120"]}, {"Citation": "Ntie-Kang F, Lifongo LL, Mbah JA, et al. In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo Basin. In Silico Pharmacol. 2013;1:12.", "ArticleIdList": ["PMC4230438", "25505657"]}, {"Citation": "Ntie-Kang F, Mbah JA, Lifongo LL, et al. Assessing the pharmacokinetic profile of the CamMedNP natural products database: an in silico approach. Org Med Chem Lett. 2013;3(1):10.", "ArticleIdList": ["PMC3767462", "24229455"]}, {"Citation": "Ongu\u00e9n\u00e9 PA, Ntie-Kang F, Mbah JA, et al. The potential of anti-malarial compounds derived from African medicinal plants, part III: an in silico evaluation of drug metabolism and pharmacokinetics profiling. Org Med Chem Lett. 2014;4(1):6.", "ArticleIdList": ["PMC4970435", "26548985"]}, {"Citation": "Wolber G, Langer T. LigandScout: 3D-pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005;45(1):160\u2013169.", "ArticleIdList": ["15667141"]}, {"Citation": "Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235\u2013242.", "ArticleIdList": ["PMC102472", "10592235"]}, {"Citation": "Chemical Computing Group Inc . Molecular Operating Environment, Version 2010. Montreal: Chemical Computing Group Inc; 2010."}, {"Citation": "Halgren TA. Merck molecular forcefield. J Comput Chem. 1996;17:490\u2013441."}, {"Citation": "Schr\u00f6dinger LLC. LigPrep Software, Version 2.5. New York: Schr\u00f6dinger LLC; 2011."}, {"Citation": "Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem. 2012;55(14):6582\u20136594.", "ArticleIdList": ["PMC3405771", "22716043"]}, {"Citation": "G\u00fcner OF, Henry DR. Pharmacophore perception, development, and use in drug design. In: G\u00fcner OF, editor. Metric for Analyzing Hit Lists and Pharmacophores; IUL Biotechnology Series. La Jolla, CA: International University Line; 2000. pp. 191\u2013212."}, {"Citation": "G\u00fcner OF, Waldman M, Hoffmann RD, Kim JH. Pharmacophore perception, development, and use in drug design. In: G\u00fcner OF, editor. Strategies for Database Mining and Pharmacophore Development. 1st Edition. La Jolla, CA: International University Line; 2000. pp. 213\u2013236. (IUL Biotechnology Series)."}, {"Citation": "Langer T, Hoffmann RD. Pharmacophores and Pharmacophore Searches. Weinheim, Germany: WILEY-VCH; 2006. pp. 338\u2013340."}, {"Citation": "Lhasa Limited [webpage on the Internet]  Derek Nexus.  [Accessed May 19, 2015].  Available from:  http://www.lhasalimited.org/products/derek-nexus.htm."}, {"Citation": "Wold S, Esbensen K, Geladi P. Principal component analysis. Chemometr Intell Lab Syst. 1987;2:37\u201352."}, {"Citation": "Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP \u2013 retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci. 1998;38(3):511\u2013522.", "ArticleIdList": ["9611787"]}, {"Citation": "ChemAxon [webpage on the Internet]  JChem Software, Version 5.11.3. 2012.  [Accessed May 19, 2015].  Available from:  https://www.chemaxon.com/jchem/doc/user/LibMCS.html."}, {"Citation": "Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 2002;62(15):4236\u20134243.", "ArticleIdList": ["12154025"]}, {"Citation": "Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-Kit receptor tyrosine kinases. Cancer Res. 2002;62(15):4244\u20134255.", "ArticleIdList": ["12154026"]}, {"Citation": "Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB. Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (Pap) derivatives. Bioorg Med Chem Lett. 1997;329(7):187\u2013192."}, {"Citation": "Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000;60(7):885\u2013898.", "ArticleIdList": ["10974196"]}, {"Citation": "McHardy T, Caldwell JJ, Cheung KM, et al. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt) J Med Chem. 2010;53(5):2239\u20132249.", "ArticleIdList": ["PMC2832868", "20151677"]}, {"Citation": "Caldwell JJ, Davies TG, Donald A, et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem. 2008;51(7):2147\u20132157.", "ArticleIdList": ["18345609"]}, {"Citation": "Donald A, McHardy T, Rowlands MG, et al. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J Med Chem. 2007;50(10):2289\u20132292.", "ArticleIdList": ["17451235"]}, {"Citation": "Wang S, Griffiths G, Midgley CA, et al. Discovery and characterization of 2-anilino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol. 2010;17(10):1111\u20131121.", "ArticleIdList": ["21035734"]}, {"Citation": "Hast MA, Fletcher S, Cummings CG, et al. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem Biol. 2009;16(2):181\u2013192.", "ArticleIdList": ["PMC2671474", "19246009"]}, {"Citation": "Battistutta R, Cozza G, Pierre F, et al. Unprecedented selectivity and structural determinants of a new class of protein kinase ck2 inhibitors in clinical trials for the treatment of cancer. Biochemistry. 2011;50(39):8478\u20138488.", "ArticleIdList": ["21870818"]}, {"Citation": "Pierre F, Stefan E, N\u00e9dellec AS, et al. 7-(4H-1,2,4-triazol-3-yl) benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011;21(22):6687\u20136692.", "ArticleIdList": ["21982499"]}, {"Citation": "Hou Z, Nakanishi I, Kinoshita T, et al. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds. J Med Chem. 2012;55(6):2899\u20132903.", "ArticleIdList": ["22339433"]}, {"Citation": "Pierre F, Regan CF, Chevrel MC, et al. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. Bioorg Med Chem Lett. 2012;22(9):3327\u20133331.", "ArticleIdList": ["22460033"]}, {"Citation": "Berg S, Bergh M, Hellberg S, et al. Discovery of novel potent and highly selective glycogen synthase kinase-3\u03b2 (GSK3\u03b2) inhibitors for Alzheimer\u2019s disease: design, synthesis, and characterization of pyrazines. J Med Chem. 2012;55(21):9107\u20139119.", "ArticleIdList": ["22489897"]}, {"Citation": "Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000;7(10):793\u2013803.", "ArticleIdList": ["11033082"]}, {"Citation": "Good JA, Wang F, Rath O, et al. Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. J Med Chem. 2013;56(5):1878\u20131893.", "ArticleIdList": ["PMC3759169", "23394180"]}, {"Citation": "Tojo S, Kohno T, Tanaka T, et al. Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors. ACS Med Chem Lett. 2014;5(10):1119\u20131123.", "ArticleIdList": ["PMC4190630", "25313323"]}, {"Citation": "Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett. 2006;27(8):861\u2013874."}, {"Citation": "Yang JM, Shen TW. A Pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators. Proteins. 2005;59(2):205\u2013220.", "ArticleIdList": ["15726586"]}, {"Citation": "Muegge I. Selection criteria for drug-like compounds. Med Res Rev. 2003;23(3):302\u2013321.", "ArticleIdList": ["12647312"]}, {"Citation": "Ntie-Kang F, Kannan S, Wichapong K, Owono Owono LC, Sippl W, Megnassan E. Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(PB)SA analysis. Mol Biosyst. 2014;10(2):223\u2013239.", "ArticleIdList": ["24240974"]}, {"Citation": "Liao HS, Liu HL, Chen WH, Ho Y. Structure-based pharmacophore modeling and virtual screening to identify novel inhibitors for anthrax lethal factor. Med Chem Res. 2014;23(8):3725\u20133732."}, {"Citation": "Koide Y, Uemoto K, Hasegawa T, et al. Pharmacophore-based design of sphingosine 1-phosphate-3 receptor antagonists that include a 3,4-dialkoxybenzophenone scaffold. J Med Chem. 2007;50(3):442\u2013454.", "ArticleIdList": ["17266196"]}, {"Citation": "Lu SH, Wu JW, Liu HL, et al. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci. 2011;18:8.", "ArticleIdList": ["PMC3036604", "21251245"]}, {"Citation": "Seal A, Yogeeswari P, Sriram D, OSDD Consortium. Wild DJ. Enhanced ranking of PknB inhibitors using data fusion methods. J Cheminform. 2013;5(1):2.", "ArticleIdList": ["PMC3600029", "23317154"]}, {"Citation": "Kalva S, Azhagiya Singam ER, Rajapandian V, Saleena LM, Subramanian V. Discovery of potent inhibitor for matrix metalloproteinase-9 by pharmacophore based modeling and dynamics simulation studies. J Mol Graph Model. 2014;49:25\u201337.", "ArticleIdList": ["24473069"]}, {"Citation": "Sanderson DM, Earnshaw CG. Computer prediction of possible toxic action from chemical structure; the DEREK system. Hum Exp Toxicol. 1991;10(4):261\u2013273.", "ArticleIdList": ["1679649"]}, {"Citation": "Greene N, Judson PN, Langowski JJ, Marchant CA. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ Res. 1999;10(2\u20133):299\u2013314.", "ArticleIdList": ["10491855"]}, {"Citation": "Marchant CA, Briggs KA, Long A. In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows, Meteor, and Vitic. Toxicol Mech Methods. 2008;18(2\u20133):177\u2013187.", "ArticleIdList": ["20020913"]}, {"Citation": "Ridings JE, Barratt MD, Cary R, et al. Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. Toxicology. 1996;106(1\u20133):267\u2013279.", "ArticleIdList": ["8571398"]}, {"Citation": "Greene N. Computer software for risk assessment. J Chem Inf Comput Sci. 1997;37(1):148\u2013150."}, {"Citation": "Marchant CA. Computational toxicology: a tool for all industries. Wiley Interdiscip Rev Comput Mol Sci. 2012;2(3):424\u2013434."}, {"Citation": "Sherhod R, Gillet VJ, Judson PN, Vessey JD. Automating knowledge discovery for toxicity prediction using jumping emerging pattern mining. J Chem Inf Model. 2012;52(11):3074\u20133087.", "ArticleIdList": ["23092382"]}, {"Citation": "Happi EN, Waffo AF, Wansi JD, Ngadjui BT, Sewald N. O-prenylated acridone alkaloids from the stems of Balsamocitrus paniculata (Rutaceae) Planta Med. 2011;77(9):934\u2013938.", "ArticleIdList": ["21243586"]}, {"Citation": "Tsassi VB, Hussain H, Meffo BY, et al. Antimicrobial coumarins from the stem bark of Afraegle paniculata. Nat Prod Commun. 2010;5(4):559\u2013561.", "ArticleIdList": ["20433072"]}, {"Citation": "Wall ME, Wani MC, Hughes TJ, Taylor H. Plant antimutagenic agents, 1. General bioassay and isolation procedure. J Nat Prod. 1988;51(5):866\u2013873.", "ArticleIdList": ["3060564"]}, {"Citation": "Zhang Y, Cao Y, Zhan Y, Duan H, He L. Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo. Fitoterapia. 2010;81(8):1188\u20131195.", "ArticleIdList": ["20691250"]}, {"Citation": "Khalid H, Abdalla WE, Abdelgadir H, Opatz T, Efferth T. Gems from traditional North-African medicine: medicinal and aromatic plants from Sudan. Nat Prod Bioprospect. 2012;2(3):92\u2013103."}, {"Citation": "National Toxicology Program (NTP) Toxicology and carcinogenesis studies of 8-methoxypsoralen (CAS No 298-81-7) in F344/N rats (gavage studies) Chapel Hill, USA: 1989. (National Toxicology Program Report, Additional Content: TR-359).", "ArticleIdList": ["12695782"]}, {"Citation": "Dall\u2019Acqua F, Terbojevich M, Marciani S, Vedaldi D, Recher M. Investigation of the dark interaction between furocoumarins and DNA. Chem Biol Interact. 1978;21(1):103\u2013115.", "ArticleIdList": ["566637"]}, {"Citation": "Quinto I, Averbeck D, Moustacchi E, Hrisoho Z, Moron J. Frameshift mutagenicity in Salmonella typhimurium of furocoumarins in the dark. Mutat Res. 1984;136(1):49\u201354.", "ArticleIdList": ["6371513"]}, {"Citation": "Ferguson LR, Denny WA. The genetic toxicology of acridines. Mutat Res. 1991;258(2):123\u2013160.", "ArticleIdList": ["1881402"]}, {"Citation": "Albertini S, B\u00f6s M, Gocke E, Kirchner S, Muster W, Wichmann J. Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay. Mutagenesis. 1998;13(4):397\u2013403.", "ArticleIdList": ["9717178"]}], "ReferenceList": []}], "History": [{"Year": "2016", "Month": "7", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "7", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2017", "Month": "5", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "7", "Day": "4"}], "PublicationStatus": "epublish", "ArticleIdList": ["27445461", "PMC4938243", "10.2147/DDDT.S108118", "dddt-10-2137"]}}], "PubmedBookArticle": []}